Replies to post #161065 on Avid Bioservices Inc (CDMO)

[entdoc]

FTM..I almost wrote the same re. liver and pancreas. We have to be realistic about these horrendous diseases, and the limited role chemotherapy can play in advanced disease. In Bavi we have a great candidate compound for early solid cancers, and for adjunctive use in surgery, irradiation, and chemo...possibly a great preventive...and probably for other inflammatory diseases. Let's be pleasantly surprised with incremental improvement, and not crash this thing if it does not perform miracles.

[Hypi]

Still don't know why they haven't released more information. Look the preferred and ATM could have been done at different levels had we run the common up to the $3 range. It seems like the ATM shares were really done for a reason and maybe all of it will become more evident in the next few weeks. I mean the stock broke $2 and then we had to run the ATM machine which caused a 20% decline. Okay you have enough dollars, so give us some goods.

[purpledawgs]

FTM: It seems like bavi was less effective with pancreatic cancer because the MOS for pancreatic was perhaps around 6 months.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=77501263

Perhaps many patients died before the mechanism of action could get revved up?

With liver cancer treated by sorafenib the MOS is more than 10 months.

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=70621607

Do you think bavi has a better chance at working with liver than pancreatic because it has longer for the mechanism of action to get going?

I appreciate your input.

pd

[md1225]

You should. Would 30% improvement over soc be considered a blockbuster drug? With no additional S/E.

Yes it would.

[horselover45]

Trying to remember as to the lead up to release of the pancreatic results. Drawing a blank. Old age and loss of memory.

Were we informed as to the release date over a month before them??Was it in the format of an oral presentation at a scientific conference? Somehow this looks a little different. Not that I am looking for spectacular but have to believe that because of the format of an oral presentation they will be decent.

Just out of curiosity do you expect at AACR to have a few of the preclinical results that we have been looking for??

Guess we will know on the 19th,
Andy C.

[dia76ca]

FTM...what would be considered to be a good result? If the Sorafenib alone arm MOS is 6 months would the Bavi + Sorafenib arm MOS of 7 months be good enough? Or would 8 months or more be necessary to draw attention to these results? Is Sorafenib perhaps not as immunostimulatory as docetaxel?